Asset profile
BIIB122 / DNL151 (LRRK2 inhibitor)
Small molecule
Evidence outlook · registrational
Parkinson's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT05348785: The study randomized 650 participants to BIIB122 or matching placebo, with participants, care providers, investigators, and outcome assessors blinded. Its primary endpoint is time to confirmed worsening on the clinical MDS-UPDRS motor and daily-living scale, but the comparison has not been reported, so the trial provides well-designed evidence with an unknown result rather than evidence of a demonstrated benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
March 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.